Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
An article from
Dive Brief
Trodelvy’s latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead’s main business.
Published June 9, 2026
A Merck sign hangs on the side of an office building in South San Francisco, California.
Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial - Gilead Sciences (NASDAQ:GILD), Merck & Co (NYS
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merck, Gilead score in effort to develop the first weekly HIV pill
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Gilead and Merck's latest trial success and flop
The era of the one-size-fits-all Cancer drug is ending
Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV…
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
A combination of Merck’s islatravir and Gilead’s lenacapavir has
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral…
